ADVERTISEMENT
Biosimilars
The importance of generic and biosimilar medicines is being recognized by the UK government for the first time. But, as Medicines UK’s CEO Mark Samuels tells Generics Bulletin, companies are still facing multiple hurdles in the market.
With eight biosimilars launching by 2027, Teva sees its biosimilars business not as a one-hit bet, but a portfolio approach. The company spoke about its plans, alongside tariffs and other topics, during its second-quarter earnings call.
Generics Bulletin previews the most noteworthy and anticipated events for August 2025.
Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?
Roche expects biosimilars to Perjeta and Xolair by the end of 2026, marking a key inflection point for two of its major franchises. Shanghai Henlius Biotech leads development for pertuzumab, while Celltrion is positioned as the frontrunner for omalizumab.
Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.
This article compiles all of the data from Generics Bulletin’s 2025 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
Celltrion is the preferred bidder for the acquisition of a large-scale cGMP biologics manufacturing plant in the US, marking a pivotal move to localize production and secure its US pharmaceutical business against rising tariff risks.
Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.
In the third instalment of this year’s Generics Bulletin Top 50, we reveal which firms have entered the ranking for the first time.
Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.
Denosumab, aflibercept and ustekinumab biosimilars received positive opinions from the EMA’s CHMP at its meeting in July, along with an Opsumit generic from Accord.